Effects of Coenzyme Q10 in PSP and CBD

This study has been completed.
Sponsor:
Information provided by:
Lahey Clinic
ClinicalTrials.gov Identifier:
NCT00532571
First received: September 18, 2007
Last updated: September 19, 2007
Last verified: September 2007

September 18, 2007
September 19, 2007
January 2004
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00532571 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Coenzyme Q10 in PSP and CBD
Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Progressive Supranuclear Palsy
  • Neurological Disorders
Drug: CoQ10
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
September 2005
Not Provided

Inclusion Criteria:

  • Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
  • Age > 40
  • Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
  • Patients agreeable to participate in the study.

Exclusion Criteria:

  • Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
  • Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
  • History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Previous use of coenzyme Q10 within 60 days of the baseline visit.
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00532571
CoQ10 with PSP/CBD
No
Not Provided
Lahey Clinic
Not Provided
Principal Investigator: Diana Apetauerova, MD Lahey Clinic
Lahey Clinic
September 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP